<DOC>
	<DOC>NCT02015481</DOC>
	<brief_summary>The Purpose of this study is to assess the Safety, Tolerability and Efficacy of Intravenous Cabaletta® in Oculopharyngeal Muscular Dystrophy (OPMD) Patients.</brief_summary>
	<brief_title>Safety Tolerability and Efficacy Study of Cabaletta to Treat Oculopharyngeal Muscular Dystrophy (OPMD) Patients</brief_title>
	<detailed_description />
	<mesh_term>Muscular Dystrophies</mesh_term>
	<mesh_term>Muscular Dystrophy, Oculopharyngeal</mesh_term>
	<criteria>Males and females 18 80 years (inclusive) of age Clinically and genetically diagnosed as OPMD Moderate dysphagia (abnormal drinking test at screening and on the first dosing day, before drug administration) Patients who provide written informed consent to participate in the study Body Mass Index (BMI) &lt;30 kg/m2 Diabetes mellitus type 1 or 2 Other major diseases, e.g.: renal failure (creatinine clearance &lt;60ml/min), liver failure and chronic liver diseases (e.g. hepatitis B or C) , HIV carriers, tuberculosis, SLE, rheumatoid polyarthritis, sarcoidosis, collagenosis Uncontrolled heart disease , CHF, Other neuromuscular diseases Other disorders associated with esophageal dysphagia: e.g. severe gastroesophageal reflux (GERD), esophageal stricture due to mechanical or chemical trauma, infection (e.g. esophageal moniliasis), druginduced dysphagia (e.g. bisphosphonates), esophageal rings and webs, spastic motility disorders of the esophagus. History of malignancy (except noninvasive skin malignancy) History of neck irradiation Pregnant or currently lactating women Obesity (BMI≥ 30) and associated morbidity Prior pharyngeal myotomy Weight loss of more than 10% in the last 12 months. Known hypersensitivity to any ingredients in the injection Patient receiving anticoagulant treatment (e.g. warfarin)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Case control, safety, tolerability, efficacy.</keyword>
</DOC>